Note: Descriptions are shown in the official language in which they were submitted.
20~3136
-- 1 --
BACKGROUND OF THE INVENTION
US Patent 4,649,144 discloses 7-(3-amino-
l-pyrrolidinyl)-l-cyclopropyl-6-fluoro-1,4-dihydro-
4-oxo-1,8-naphthyridine-3-carboxylic acid as having
antibacterial activity. In the patent, it is recognized
that there is an asymmetric carbon atom on the
pyrrolidine ring of the compound and that the compound
can exist in optically active forms. Nevertheless, the
patent does not describe the synthesis of these
optically active forms nor does it describe or suggest
which, if any, of the optically active forms would have
antibacterial activity equal, better or less than the
racemic compound, the compound specifically described in
the patent.
We have now found that the S form of 7-(3-amino-
l-pyrrolidinyl)-l-cyclopropyl-6-fluoro-1,4-dihydro-
4-oxo-1,8-naphthyridine-3-carboxylic acid has
significantly better activity against both gram-positive
and gram-negative bacteria in vitro as well as in vivo.
The S isomer is surprisingly not only better than its
opposite R isomer but also better than the racemic
compound described in the above patent.
SUMMARY OF THE INVENTION
Accordingly, the present invention is directed to
the S optical isomer of 7-(3-amino-1-pyrrolidinyl)-
l-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyri-
dine-3-carboxylic acid, its lower alkyl esters or a
pharmaceutically acceptable ~cid addition or base salt
thereof.
The present invention also concerns a
pharmaceutical composition containing the above compound
together with a pharmaceutical excipient in a dosage
form for treating bacterial infections.
2Q13136
- 2 -
Finally, the present invention is directed to a
method of treating bacterial infections in mammals by
administering to said mammal in need thereof an
antibacterially effective amount of the aDoVe compound
in unit dosage form.
DETAILED DESCRIPTION
Compounds of the present invention may be readily
prepared by treating a 7-halo-1-cyclopropyl-6-fluoro-
1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid or
a lower alkyl ester wherein lower alkyl is one to
four carbon atoms, with an (S)-3-[[lower alkyloxy-
carbonyl]amino]pyrrolidine in the presence of base and
optionally in the presence of an organic solvent at
approximately ambient to somewhat elevated temperatures,
e.g., 25-100~C.
Other blocking groups, in addition to lower
alkyloxycarbonyl groups, can be formyl, acetyl,
trifluoroacetyl; ~ -trichloroethoxycarbonyl,
~-iodoethoxycarbonyl; aryloxycarbonyl group such as
benzyloxycarbonyl, ~-methoxybenzyloxycarbonyl,
phenoxycarbonyl; silyl groups such as trimethylsilyl;
- and groups such as trityl, tetrahydropyranyl,
vinyloxycarbonyl, o-nitrophenyl, sulfenyl,
diphenylphosphinyl, ~-toluenesulfonyl, and benzyl. As
stated above, the groups may be removed by acid
hydrolysis but also can be removed by base hydrolysis,
and the trityl group, for example, may be removed by
hydrogenolysis.
In addition to ambient temperatures, the reaction
between the protected aminopyrrolidine and the
haloquinoline can be carried out in a range of from 20~C
to about 150~C; higher temperatures usually require
shorter reaction times and may be prepared from known
~_ _ 3 _ 20~3~3~
starting materials by standard procedures or by
variations thereof.
For example, 7-chloro-1-cyclopropyl-6-fluoro-
1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
may be prepared by a series of reactions starting from
4-(6-chloro-3-nitro-2-pyridinyl)-1-piperazinecarboxylic
acid, ethyl ester. The intermediate, 1-cyclopropyl-
6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naph-
thyridine-3-carboxylic acid can be converted to the
7-hydroxy derivative with a mixture of nitric and
sulfuric acids which is then replaced by chlorine by
treatment with phosphorus oxychloride to give the
desired intermediate. The synthesis of both of the
above N-cyclopropyl intermediates is described in the
Preparative Examples.
The (S)-protected aminopyrrolidine may be prepared
in accordance with the procedures described in the
examples herein.
The compounds of the invention are capable of
forming both pharmaceutically acceptable acid addition
and/or base salts. Base salts are formed with metals or
amines, such as alkali and alkaline earth metals or
organic amines. Examples of metals used as cations are
sodium; potassium, magnesium, calcium, and the like.
Also included are heavy metal salts such as for example
silver, zinc, cobalt, and cerium. Such heavy metal
salts are effective in the treatment of burns especially
when applied to the affected surface of a burn victim
either directly or in combination with a physiologically
acceptable carrier such as a water dispersible,
hydrophilic carrier. Examples of suitable amines are
N,N'dibenzylethylenediamine, chloroprocaine, choline,
diethanolamine, ethylenediamine, N-methylglucamine, and
procaine.
Pharmaceutically acceptable acid addition salts are
formed with organic and inorganic acids.
Z(~3136
~- - 4 -
Examples of suitable acids for salt formation are
hydrochloric, sulfuric, phosphoric, acetic, citric,
oxalic, malonic, salicylic, malic, gluconic, fumaric,
succinic, ascorbic, maleic, methanesulfonic, and the
like. The salts are prepared by contacting the free
base form with a sufficient amount of the desired acid
to produce either a mono or di, etc salt in the
conventional manner. The free base forms may be
regenerated by treating the salt form with a base. For
example, dilute solutions of aqueous base may be
utilized. Dilute aqueous sodium hydroxide, potassium
carbonate, ammonia, and sodium bicarbonate solutions are
suitable for this purpose. The free base forms differ
from their respective salt forms somewhat in certain
physical properties such as solubility in polar
solvents, but the salts are otherwise equivalent to
their respective free base forms for purposes of the
invention. Use of excess base gives the corresponding
basic salt.
The compounds of the invention can exist in un-
solvated as well as solvated forms, including hydrated
forms. In general, the solvated forms, including
hydrated forms and the like are equivalent to the
unsolvâted forms for purposes of the invention.
The alkyl groups contemplated by the invention
comprise both straight and branched carbon chains of
from one to about three carbon atoms except when
specifically stated to be greater than three carbon
atoms. Representative of such groups are methyl, ethyl,
propyl, isopropyl, and the like.
The alkoxy groups contemplated by the invention
comprise both straight and branched carbon chains of
from one to about six carbon atoms unless otherwise
specified. Representative of such groups are methoxy,
ethoxy, propoxy, l-propoxy, t-butoxy, hexoxy, and the
like.
136
-- 5 --
The term halogen or halo is intended to include
fluorine, chlorine, bromine, and iodine unless otherwise
specified.
The compounds of the invention can be prepared and
administered in a wide variety of oral, parenteral and
topical dosage forms. It will be obvious to those
skilled in the art that the following dosage forms may
comprise as the active component, a compound of the
present invention or a corresponding pharmaceutically
acceptable salt thereof.
For preparing pharmaceutical compositions from the
compounds described by this invention, inert,
pharmaceutically acceptable carriers can be either solid
or liquid. Solid form preparations include powders,
tablets, dispersible granules, capsules, cachets,
suppositories, and ointments. A solid carrier can be
one or more substances which may also act as diluents,
flavoring agents, solubilizers, lubricants, suspending
agents, binders, or tablets disintegrating agents; it
can also be an encapsulating material. In powders, the
carrier is a finely divided solid which is in admixture
with the finely divided active compound. In the tablet
the active compound is mixed with carrier having the
necessary binding properties in suitable proportions and
compacted in the shape and size desired. The powders
and tablets preferably contain from 5 or 10 to about
70 percent of the active ingredient. Suitable solid
carriers are magnesium carbonate, magnesium stearate,
talc, sugar, lactose, pectin, dextrin, starch, gelatin,
tragacanth, methyl cellulose, sodium carboxymethyl
cellulose, a low melting wax, cocoa butter, and the
like. The term "preparation" is intended to include the
formulation of the active compound with encapsulating
material as carrier providing a capsule in which the
active component (with or without other carriers) is
surrounded by carrier, which is thus in association with
~131~i
-- 6 --
it. Similarly, cachets are included. Tablets, powders,
cachets, and capsules can be used as solid dosage forms
suitable for oral administration.
Liquid form preparations include solutions,
5 suspensions and emulsions. As an example may be
mentioned water or water-propylene glycol solutions for
parenteral injection. Such solutions are prepared so as
f to be acceptable to biological systems (isotonicity, pH,
etc). Li~uid preparations can also be formulated in
10 solution in aqueous polyethylene glycol solution.
Aqueous solutions suitable for oral use can be prepared
by dissolving the active component in water and adding
suitable colorants, flavors, stabilizing, and thickening
agents as desired. Aqueous suspension suitable for oral
15 use can be made by dispersing the finely divided active
component in water with viscous material, i.e., natural
or synthetic gums, resins, methyl cellulose, sodium
carboxymethyl cellulose, and other well-known suspending
agents.
Ointment preparations contain heavy metal salts of
a compound of Formula I with a physiologically
acceptable carrier. The carrier is desirably a
conventional water-dispersible hydrophilic or
oil-in-water carrier, particularly a conventional
semi-soft or cream-like water-dispersible or water
soluble, oil-in-water emulsion which may be applied to
an affected burn surface or infected surface with a
minimum of discomfort. Suitable compositions may be
prepared by merely incorporating or homogeneously
admixing finely divided compounds with the hydrophilic
carrier or base or ointment.
Preferably, the pharmaceutical preparation is in
unit dosage form. In such form, the preparation is
subdivided into unit doses containing appropriate
quantities of the active component. The unit dosage
- 7 -
form can be a packaged preparation, the package con-
taining discrete quantities of preparation, for example,
packeted tablets, capsules, powders in vials or
ampoules, and ointments in tubes or jars. The unit
dosage form can also be a capsule, cachet, tablet, gel
or cream itself or it can be the appropriate number of
any of these packaged forms.
The ~uantity of active compound in a unit dose of
preparation may be varied or adjusted from 1 mg to
100 mg according to the particular application and the
potency of the active ingredient.
In therapeutic use as agents for treating bacterial
infections the compounds utilized in the pharmaceutical
method of this invention are administered at the initial
dosage of about 3 mg to about 40 mg per kilogram daily.
A daily dose range of about 6 mg to about 14 mg per
kilogram is preferred. The dosages, however, may be
varied depending upon the requirements of the patient,
the severity of the condition being treated, and the
compound being employed. Determination of the proper
dosage for a particular situation is within the skill of
the art. Generally, treatment is initiated with smaller
dosages which are less than the optimum dose of the
compound. Thereafter, the dosage is increased by small
increments until the optimum ef~ect under the circum-
stances is reached. For convenience, the total daily
dosage may be divided and administered in portions
during the day if desired.
The compounds of the invention display
antibacterial activity when tested by the microtitration
dilution method as described in Heifetz, et al,
Antimicr. Agents and Chemot. 6, 124 (1974).
By the use of the above reference method, the
following minimum inhibitory concentration v,alues
(MICs in ~g/ml) were obtained for
~Q~3136
the compound of the present invention, (S)-7-(3-amino-
l-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-
4-oxo-1,8-naphthyridine-3-carboxylic acid, the
corresponding (R) isomer and the racemic compound as
described in US Patent 4,649,144.
In addition to the MIC data in the following table
for the above compounds, there is also provided
in vivo data.
The in vivo experiments on the bacteria named are
expressed in terms of median protective doses (PD50) on
the test animals to which the compounds were
administered orally and subcutaneously. The measurement
of PD50 was carried out according to the following
procedure:
Therapeutic activities of the compounds were
compared in acute mouse protection tests in which
18-22 g female Charles River CD-1 mice were used. Oral
and subcutaneous doses in twofold rising incremental
series were administered concurrently with bacterial
challenge. Challenges were accomplished by the
intraperitoneal injection of an estimated 100 median
lethal doses in 0.5 ml volumes of 5% hog gastric mucin
or tryptic soy broth. Generally, greater than 90% of
the untreated controls died within 48-72 hours. Final
survival percentages, obtained after 4-7 days of
observation among groups of 8-16 mice, were used to
estimate median protective doses (PD50) by the
log-probit method.
3~3~ -
V , ~
o ~ ~ d1
C~ ~ ,,
~, o
~i Q
~ o
o
~ ~ U
V oo o ,1 o ~ o
.........
~:OOoooooooo
U~
C~
o
tn
a) O
o~
O
o
U~
V o o o o ~ ~ o
.........
~oooooooooo
a~ Ln
V
O ~ d'
U~
o
~ ~n
o :4 ~ r'
U\ O
~ o ~ ~C~
V~
~ o ~ ~ ln ~ ~n u)
V O O O O ~ O O ~10 0
H - ~ . . . . . .. . .
OOOOOOOOOO
~O 00 11
0~ ~ ~~ O
H ~ l ~ I
V ~1 U
U
ar~u~ u~ u~ ~ q
C ~ ~ ~~o
, 1) ~ r~
a
~ o
O
U o ~ ~ ~ U U U
r r
~ ~ ~J J ~_ _
t~ ~J U~r~) ~Jr~ J J
' ) O'J
Ul~,).~-~1~VUUOO
~a r,--~ O O OO C~ ~J
u ,q ,a)UlE~ ~ ~ ~G O
'' ~ ~ O ~
- h a rr
r ~ O
U ~ ~ U~ ~ ~ ~ ~
'~ -- 10 --
The following examples are illustrative of the
present invention.
PREPARATION OF THE (S) AND (R) 3-PROTECTED
AMINOPYRROLIDINES
(S)-3-Hydroxypyrrolidine
A solution of 22.5 g (105 mmol) of 1-benzyl-3(S)-
pyrrolidinol (J. Am. Chem. Soc., 1986, 108, 2049)
hydrochloride in 400 ml of methanol was treated with
2.0 g of 20% palladium on carbon and shaken in an
atmosphere of hydrogen at temperatures of 23-26.5~C and
pressures of 48.4-51.2 psi for 21 hours. The catalyst
was removed by filtration through Celite and the solvent
was removed in vacuo to give 12.9 g of the title
compound as a light yellow oil.
(R)-3-Hydroxypyrrolidine
The above procedure was followed using 30.4 g
(142 mmol) of 1-benzyl-3(R)-pyrrolidinol (J. Am. Chem.
Soc., 1986, 108, 2049) hydrochloride, 600 ml of
methanol, and 3.0 g of 20% palladium on carbon to give
14.8 g of the title compound as a light yellow oil.
(R)-3-Hydroxy-l-pyrrolidinecarboxylic acid, phenylmethyl
ester
A solution of 10.2 g (82.6 mmol) of R-3-hydroxy-
pyrrolidine hydrochloride (Chem. Letts., 1966, pp 893-6)
in 50 ml of water was cooled to 0~ and treated with
22.5 ml (90 mmol) of 4.0 N sodium hydroxide. The
neutral solution was treated dropwise with 15.6 g
(87 mmol) of carbobenzyloxy chloride maintaining the pH
at 11.0 ~ 0.5 by the dropwise addition of 87 ml of 1.0 N
sodium hydroxide and the temperature below 5~ with a
salt-ice bath. When the addition was complete, the
mixture was stirred at 5~ for two hours and stored at 5~
~Q~
1 1 --
for 18 hours. The reaction mixture was saturated with
sodium chloride and extracted with ethyl acetate
(2 x 500 ml). The combined organic layers were washed
with 1.0 N sodium hydroxide (4 x 50 ml), water, dried
(MgS04) and evaporated in vacuo to give 17.5 g of the
title compound.
(S)-3-Hydroxy-1-pyrrolidinecarboxylic acid, phenyl-
methyl ester
When the above procedure was repeated using 12.4 g
(0.1 mol) of (S)-3-hydroxypyrrolidine hydrochloride, the
yield of the title compound was 20.1 g.
(R)-3-[(Methylsulfonyl)oxy]-1-pyrrolidinecarboxylic
acid, phenylmethyl ester
A solution of 17.5 g (84 mmol) of (R)-3-hydroxy-
1-pyrrolidinecarboxylic acid, phenylmethyl ester in
150 ml of dry pyridine was cooled to 5~ and treated
dropwise with 11.5 g (0.1 mol) of methanesulfonyl
chloride keeping the temperature at 5~. The reaction
mixture was stirred at 5~ for two hours and stored at 5~
for 18 hours. The reaction mixture was allowed to warm
to room temperature over three hours and the solvent was
then removed in vacuo. The residue was partitioned
between ethyl acetate/water (500 ml each) and the
aqueous layer was reextracted with ethyl acetate. The
combined organic layers were washed with water, dried
(MgS04), and evaporated in vacuo to give 21.2 g of the
title compound.
(_)-3-~(Methylsulfonyl)oxy]-1-pyrrolidinecarboxylic
acid, phenylmethyl ester
When the above reaction was run using 19.7 g
(89 mmol) of the (S)-isomer, the yield of the title
compound was 26.2 g.
- 12 -
(_)-3-Azido-1-pyrrolidinecarboxylic acid, phenylmethyl
ester
A solution of 20.5 g (72 mmol) of (R)-3-[(methyl-
sulfonyl)oxy]-1-pyrrolidinecarboxylic acid, phenylmethyl
ester in 100 ml of dry N,N-dimethylformamide was treated
with 6.5 g (0.1 mol) of sodium azide and heated at 90~
for four hours. The solvent was removed in high vacuo
at 50~ and the residue was partitioned between ethyl
acetate/water (250 ml each). The a~ueous layer was
reextracted with ethyl acetate and the combined organic
fractions were washed with water, dried (MgSO4) and
evaporated in vacuo to give 16.2 g of the title
compound.
(R)-3-Azido-1-pyrrolidinecarboxylic acid, phenylmethyl
ester
When the above reaction was run using 21.0 g
(70 mmol) of the S-isomer, the yield of the title
compound was 15.2 g.
(S)-3-Amino-1-pyrrolidinecarboxlyic acid, phenylmethyl
ester
A solution of 14.7 g (60 mmol) of (S)-3-azido-1-
pyrrolidinecarboxylic acid, phenylmethyl ester in 200 ml
of methanol was treated with 1.0 g of Raney-nickel and
shaken in a hydrogen atmosphere at pressures of
49.5-51 psi and temperatures of 25.3-29.5~ for
nine hours. The catalyst was removed by filtration and
the solvent was removed in vacuo to give 13.2 g of the
title compound.
(R)-3-Amino-1-pyrrolidinecarboxylic acid, phenylmethyl
ester
When the above reaction was run using 15.1 g
(61 mmol) of the (R)-isomer, the yield of the title
compound was 13.4 g.
13 -
(S)-3-[[(1,1-Dimethylethoxy)carbonyl]amino]-l-
pyrrolidinecarboxylic acid, phenylmethyl ester
To a solution of 13.7 g (60 mmol) of (S-3-amino-
1-pyrrolidinecarboxylic acid, phenylmethyl ester in a
mixture of 59 ml of 1.0 N sodium hydroxide and 90 ml of
t-butanol was added dropwise a solution of 13.1 g
(60 mmol) of di-tert-butyl dicarbonate in 20 ml of
t-butanol keeping the temperature below 40~. The
reaction was allowed to come to room temperature over
18 hours and the t-butanol was evaporated in vacuo. The
residue was partitioned between ethyl acetate/water
(250 ml of each) and the aqueous layer was reextracted
with ethyl acetate (250 ml). The combined ethyl acetate
layers were washed with water, dried (MgS04), filtered,
and evaporated in vacuo to give 18.2 g of the title
compound, mp 124-125~.
(R)-3-[[(1,1-Dimethylethoxy)carbonyl]amino]-1-
pyrrolidinecarboxylic acid, phenylmethyl ester
When the above reaction was run using 17.6 g
(80 mmol) of (R)-3-amino-1-pyrrolidinecarboxylic acid,
phenylmethyl ester, the yield of the title compound was
24.8 g.
(S)-3-[[(1,1-Dimethylethoxy)carbonyl]amino]pyrrolidine
A solution of 17.7 g (55.2 mmol) of
(S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-
1-pyrrolidinecarboxylic acid, phenylmethyl ester, in
400 ml of methanol was treated with 2.0 g of 20%
palladium on carbon and shaken in an atmosphere of
hydrogen at temperatures of 22-26.5~ and pressures of
45-50.5 psi for one hour. The solvent was removed in
vacuo to give 10.1 g of the title compound.
~0~31;~6
- 14 -
" ~ ~ .
(R)-3-[[(1,1-Dimethylethoxy)carbonyl]amino]pyrrolidine
When the above reaction was run using 22.4 g
(70 mmol) of (R)-3-[[(1,1-dimethylethoxy)carbonyl]-
amino]-1-pyrrolidinecarboxylic acid, phenylmethyl ester,
the yield of the title compound was 12.5 g.
EXAMPLE 1
(S)-1-Cyclopropyl-7-[3-[[(1,1-dimethylethoxy)carbonyl]-
amino]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-
naphthyridine-3-carboxylic acid
A suspension of 1.13 g (4.0 mmol) of 7-chloro-1-
cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-
3-carboxylic acid, 1.3 g (7.0 mmol) of (S)-3-[[(1,1-
dimethylethoxy)carbonyl]amino]pyrrolidine, 1.2 g
(12 mmol) of triethylamine and 50 ml of acetonitrile was
stirred at room temperature for 24 hours. The mixture
was cooled to 5~, the solid was removed by filtration,
washed with acetonitrile, ether, and dried in vacuo to
give 1.5 g of the title compound, mp 247-249~, which was
used for the next step without further purification.
EXAMPLE 2
(~)-1-Cyclopropyl-7-~3-[[(1,1-dimethylethoxy)carbonyl]-
amino]-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-1,8-
naphthyridine-3-carboxylic acid
When the above reaction was run using 1.3 g
(7.0 mmol) of (R)-3-[[(1,1-dimethylethoxy)carbonyl]-
amino]pyrrolidine, the yield of the title compound was
1.4 g (85%).
2~)~l31~6
15 -
EXAMPLE 3
(S)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-
1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
A suspension of 1.5 g (3.6 mmol) of
(S)-1-cyclopropyl-7-[3-[[(1,1-dimethylethoxy)carbonyl]-
amino]-l-pyrrolidinyl]-6-fluoro-1,4-dihydro-4-oxo-
1,8-naphthyridine-3-carboxylic acid in a solution of
25 ml of 1.0 M hydrochloric acid and 25 ml of ethanol
was stirred at room temperature for one-half hour and
then heated to 60~ for one-half hour. The resulting
solution was cooled to room temperature, filtered
through a fiber glass pad to clarify, and the filtrate
was evaporated. The residue was triturated with
2-propanol (25 ml), diluted with ether (25 ml), and the
solid was removed by filtration. After washing with
2-propanol/ether (2 x 10 ml of 1:1) ether and drying in
vacuo, the yield of the title compound was 1.18 g and
melted 296-298~.
EXAMPLE 4
(R)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl)-6-
fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-
carboxylic acid hydrochloride
When the above procedure was carried out using
1.4 g (3.4 mmol) of (R)-1-cyclopropyl-7-[3-[[(1,1-
dimethylethoxy)carbonyl]amino]-1-pyrrolidinyl]-6-fluoro-
1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
the yield of the title compound was 1.1 g and melted
2g7-299~ .
